Valuation of an Asian Healthtech Company
CIGP performed an independent valuation analysis of a Southeast Asian healthtech start-up, thereby supporting the investment decision of private and institutional investors.
Transaction Highlights
CIGP was mandated by private and institutional investors to perform an independent valuation analysis on a fast growing healthtech platform located in Asia. CIGP’s work was a key element in their decision-making process, providing a different and challenging perspective.
The target venture company is a leading healthtech player, providing a range of consumer-focused digital healthcare services, connecting millions of patients with hundreds of thousands of healthcare providers globally.
Role of CIGP
Independent valuation: CIGP leveraged its compelling expertise of the healthcare and technology sectors, together with its Emerging Markets’ experience, to provide a detailed business plan review coupled with in-depth valuation analysis.
Business plan review: CIGP critically assessed and challenged the target’s business plan, its assumptions and drivers, through bottom up due-diligence and market research.
